Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks Inc. has demonstrated significant clinical advancements with its clinical candidate, zanidatamab, showing highly statistically significant improvements in progression-free survival and overall survival in combination therapies, which positions it favorably against traditional therapies. The company is transitioning to a royalty-driven business model, with projected peak risk-adjusted sales of $1.5 billion for Ziihera, bolstered by attractive mid-single-digit royalty streams from partnerships, contributing to its robust financial outlook. With a cash position of $299 million and an additional $440 million in potential near-term milestones, Zymeworks is well-equipped to sustain its innovative R&D while capitalizing on its commercial opportunities.

Bears say

Zymeworks Inc faces significant challenges that contribute to a negative outlook on its stock. Key risks include the potential failure of core assets like zanidatamab in clinical trials, which could halt development and exert downward pressure on the stock. Additionally, the company may struggle with capital constraints and dilution risks if it fails to secure financing under favorable market conditions, potentially leading to insolvency.

Zymeworks Inc (ZYME) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Zymeworks Inc (ZYME) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.